The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin ...

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours today on fourth-quarter results that topped the consensus ...

ViCentra announced today that it appointed Tom Arnold as its new CEO to accelerate growth with the Kaleido automated insulin ...

Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented ...

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults ...

In an “urgent medical device correction,” the company urges clinicians to remind patients to monitor their glucose levels during takeoffs and landings.

New Delhi, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The global insulin pump market valuation is poised to reach US$ 25.40 billion by 2033, with a CAGR of 17.2% during the forecast period from 2025 to 2033.

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.